Brief: Zoetis Receives European Commission Marketing Authorization For Portela® (Relfovetmab) To Alleviate Pain Associated With Osteoarthritis In Cats
29/10/2025 13:06
Zoetis Inc ZTS.N: ZOETIS RECEIVES EUROPEAN COMMISSION MARKETING AUTHORIZATION FOR PORTELA® (RELFOVETMAB) TO ALLEVIATE PAIN ASSOCIATED WITH OSTEOARTHRITIS IN CATS ZOETIS INC - ANTICIPATES PORTELA AVAILABILITY IN EU IN 2026 Source text: ID:nBw5n10C1a Further company coverage: ZTS.N
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies